Export 13 results:
Author Title [ Type(Desc)] Year
Filters: Author is Robb, Merlin L  [Clear All Filters]
Journal Article
P. Pitisuttithum, Rerks-Ngarm, S., Stablein, D., Dawson, P., Nitayaphan, S., Kaewkungwal, J., Michael, N. L., Kim, J. H., Robb, M. L., O'Connell, R. J., Yoon, I. - K., Fernandez, S., and Excler, J. - L., Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand., PLoS One, vol. 10, no. 5, p. e0127998, 2015.
A. Letizia, Eller, M. A., Polyak, C., Eller, L. Anne, Creegan, M., Dawson, P., Bryant, C., D, K., Crowell, T. A., Lombardi, K., Rono, E., Robb, M. L., Michael, N. L., Maswai, J., and Ake, J. A., Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans., J Infect Dis, vol. 219, no. 2, pp. 284-294, 2019.
K. Modjarrad, Lin, L., George, S. L., Stephenson, K. E., Eckels, K. H., De La Barrera, R. A., Jarman, R. G., Sondergaard, E., Tennant, J., Ansel, J. L., Mills, K., Koren, M., Robb, M. L., Barrett, J., Thompson, J., Kosel, A. E., Dawson, P., Hale, A., C Tan, S., Walsh, S. R., Meyer, K. E., Brien, J., Crowell, T. A., Blazevic, A., Mosby, K., Larocca, R. A., Abbink, P., Boyd, M., Bricault, C. A., Seaman, M. S., Basil, A., Walsh, M., Tonwe, V., Hoft, D. F., Thomas, S. J., Barouch, D. H., and Michael, N. L., Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials., Lancet, vol. 391, no. 10120, pp. 563-571, 2018.
M. L. Robb, Eller, L. A., Kibuuka, H., Rono, K., Maganga, L., Nitayaphan, S., Kroon, E., Sawe, F. K., Sinei, S., Sriplienchan, S., Jagodzinski, L. L., Malia, J., Manak, M., de Souza, M. S., Tovanabutra, S., Sanders-Buell, E., Rolland, M., Dorsey-Spitz, J., Eller, M. A., Milazzo, M., Li, Q., Lewandowski, A., Wu, H., Swann, E., O'Connell, R. J., Peel, S., Dawson, P., Kim, J. H., and Michael, N. L., Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand., N Engl J Med, vol. 374, no. 22, pp. 2120-30, 2016.
M. L. Robb, Rerks-Ngarm, S., Nitayaphan, S., Pitisuttithum, P., Kaewkungwal, J., Kunasol, P., Khamboonruang, C., Thongcharoen, P., Morgan, P., Benenson, M., Paris, R. M., Chiu, J., Adams, E., Francis, D., Gurunathan, S., Tartaglia, J., Gilbert, P., Stablein, D., Michael, N. L., and Kim, J. H., Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144., Lancet Infect Dis, vol. 12, no. 7, pp. 531-7, 2012.
T. A. Crowell, Colby, D. J., Pinyakorn, S., Sacdalan, C., Pagliuzza, A., Intasan, J., Benjapornpong, K., Tangnaree, K., Chomchey, N., Kroon, E., de Souza, M. S., Tovanabutra, S., Rolland, M., Eller, M. A., Paquin-Proulx, D., Bolton, D. L., Tokarev, A., Thomas, R., Takata, H., Trautmann, L., Krebs, S. J., Modjarrad, K., McDermott, A. B., Bailer, R. T., Doria-Rose, N., Patel, B., Gorelick, R. J., Fullmer, B. A., Schuetz, A., Grandin, P. V., O'Connell, R. J., Ledgerwood, J. E., Graham, B. S., Tressler, R., Mascola, J. R., Chomont, N., Michael, N. L., Robb, M. L., Phanuphak, N., and Ananworanich, J., Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial., Lancet HIV, vol. 6, no. 5, pp. e297-e306, 2019.
K. Modjarrad, Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M. - D., Lamarre, C., Zaidi, F. I., Boyer, J., Kudchodkar, S. B., Jeong, M., Darden, J. M., Park, Y. K., Scott, P. T., Remigio, C., Parikh, A. P., Wise, M. C., Patel, A., Duperret, E. K., Kim, K. Y., Choi, H., White, S., Bagarazzi, M., May, J. M., Kane, D., Lee, H., Kobinger, G., Michael, N. L., Weiner, D. B., Thomas, S. J., and Maslow, J. N., Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial., Lancet Infect Dis, vol. 19, no. 9, pp. 1013-1022, 2019.
H. Kibuuka, Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A. B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L. Anne, Bailer, R. T., Koup, R. A., Nabel, G. J., Mascola, J. R., Sullivan, N. J., Graham, B. S., Roederer, M., Michael, N. L., Robb, M. L., and Ledgerwood, J. E., Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial., Lancet, vol. 385, no. 9977, pp. 1545-54, 2015.
P. Pitisuttithum, Rerks-Ngarm, S., Bussaratid, V., Dhitavat, J., Maekanantawat, W., Pungpak, S., Suntharasamai, P., Vanijanonta, S., Nitayapan, S., Kaewkungwal, J., Benenson, M., Morgan, P., O'Connell, R. J., Berenberg, J., Gurunathan, S., Francis, D. P., Paris, R., Chiu, J., Stablein, D., Michael, N. L., Excler, J. - L., Robb, M. L., and Kim, J. H., Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand., PLoS One, vol. 6, no. 12, p. e27837, 2011.
S. Rerks-Ngarm, Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P., and Kim, J. H., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand., N Engl J Med, vol. 361, no. 23, pp. 2209-20, 2009.
D. H. Barouch, Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., M Iampietro, J., SanMiguel, A., Seaman, M. S., Ferrari, G., Forthal, D. N., Ourmanov, I., Hirsch, V. M., Carville, A., Mansfield, K. G., Stablein, D., Pau, M. G., Schuitemaker, H., Sadoff, J. C., Billings, E. A., Rao, M., Robb, M. L., Kim, J. H., Marovich, M. A., Goudsmit, J., and Michael, N. L., Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys., Nature, vol. 482, no. 7383, pp. 89-93, 2012.
P. K. Ehrenberg, Shangguan, S., Issac, B., Alter, G., Geretz, A., Izumi, T., Bryant, C., Eller, M. A., Wegmann, F., Apps, R., Creegan, M., Bolton, D. L., Sekaly, R. P., Robb, M. L., Gramzinski, R. A., Pau, M. G., Schuitemaker, H., Barouch, D. H., Michael, N. L., and Thomas, R., A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials., Sci Transl Med, vol. 11, no. 507, 2019.
J. Ananworanich, Eller, L. Anne, Pinyakorn, S., Kroon, E., Sriplenchan, S., Fletcher, J. Lk, Suttichom, D., Bryant, C., Trichavaroj, R., Dawson, P., Michael, N., Phanuphak, N., and Robb, M. L., Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand., J Int AIDS Soc, vol. 20, no. 1, p. 21652, 2017.